The Life Cycle of Plasmodium spp and Malaria Vaccine Status 2013

It has been 40 years since David Clyde’s landmark induction of sterile immunity against deadly falciparum malaria through immunization by exposure to 1000 irradiated mosquitoes, and the first recombinant Plasmodium falciparum vaccine, RTS,S/AS01, is now in Phase III testing. Interim reports from this largest ever Phase III pediatric trial in Africa show the malaria vaccine decreased clinical and severe disease by 56% and 47% respectively in 5 - 17 month olds, and by 31% and 26% respectively in infants participating in the Expanded Programme on Immunization.Targets for a vaccine to protect against placental malaria, the leading remediable cause of low birth weight infants in Africa, have been identified. Lastly, renewed efforts are underway to develop a practical attenuated-sporozoite vaccine to recapture the promise of David Clyde’s experiment.

Read more:
Malaria Vaccine Status 2013

Sporce: Elsevierhealth

Art and Science of Laboratory Medicine

Web site: laboratoryeqas.exai.com

Facebook: www.facebook.com/LaboratoryEQAS

Twitter: LaboratoryEQAS